Background: Anagen effluvium with reversible scalp alopecia is a known side effect of chemotherapy. However, there are an increasing number of reports in the literature documenting permanent alopecia in patients treated with taxanes.
complete by 8 weeks, and hair regrowth is expected within 3 to 6 months upon cessation of treatment. 3 However, as described in patients who have undergone bone marrow transplants, occasionally there is only partial hair regrowth with development of permanent alopecia. [4] [5] [6] [7] [8] [9] [10] In the past few years, there have been an increasing number of reports of permanent alopecia developing in breast cancer patients treated with taxanes. [11] [12] [13] [14] [15] [16] [17] The histopathologic criteria for this particular subset population are scant 12, 13, 18 and not entirely defined. 18 This may be in part a reflection of these patients presenting with advanced/end-stage alopecia, after the irreversible damage to the hair follicles has occurred. 17 Therefore, ascertaining the morphobiologic initiating clues to hair loss remains a challenging task.
In this retrospective study, we collected a cohort of 10 breast cancer patients treated with standard protocol regimens including taxanes and adjuvant hormonal therapy and who subsequently developed permanent alopecia. Our scope was to review the histopathologic findings of these patients' alopecias, with the goal to identify any additional histopathologic morphobiologic clues, to correlate them clinically, but also to identify the role of adjuvant hormonal therapy as a pathogenic cofactor in this type of alopecia.
METHODS
The study was approved by the Guy's and St Thomas' NHS Trust, London, United Kingdom and a Research and Development registration number RJ114/N103 was allocated and entered in the Trust's Research database.
This retrospective study incorporated data from April 2010 to August 2013. The 10 patients were collected from different sources. Six patients (6/10) originated from the hair clinic in St. John's Institute of Dermatology, and 2 patients (2/10) were outside histopathology cases sent to the Department of Dermatopathology at St John's Institute of Dermatology for a second opinion. One case (1/ 10) was contributed by the Department of Dermatology at Boston University School of Medicine (Boston, MA), and 1 case (1/10) was contributed by the Institute of San Gallicano, Istituti Fisioterapici Ospitalieri (Rome, Italy).
Patients
All 10 patients were females with a history of breast cancer and alopecia lasting [6 months after cessation of combination chemotherapy with taxanes and adjuvant hormonal therapy. None of the patients had a previous history of hair loss.
Patient 6 had a total hysterectomy at 41 years of age without hair loss at the time (20 years before breast cancer and chemotherapy). She had undergone hormone replacement therapy (HRT) for 10 years without any hair loss upon withdrawal. There was also a background of clinical depression and hypothyroidism. Patient 7 had been treated for hypothyroidism and had a history of androgenic alopecia in her father. Follow-up was $18 months postchemotherapy in all patients. Hair loss history and baseline clinical photographs of the scalp were taken. The clinical pattern of alopecia of the scalp and other body sites was evaluated. Patients' age, chemotherapy regimen, coadjuvant hormonal therapy, and history of hair regrowth was also recorded.
Laboratory investigations included a complete blood cell count, renal and liver function tests, serum iron, ferritin, thyroid-stimulating hormone, and a full hormone profile (ie, total testosterone, free testosterone, dehydroepiandrosterone sulfate, progesterone, oestradiol, follicle-stimulating hormone, and luteinizing hormone levels).
Histopathology
Examination of horizontally and vertically oriented hematoxylineeosin-stained histologic sections from 4.0-mm punch biopsy specimens of the scalp were studied. The following histopathologic features were assessed: number of follicular units, total number of hair follicles, number of terminal anagen, catagen/telogen, and the number of vellus hair follicles. The histologic sections were evaluated for the presence or absence of sebaceous glands, pigment casts, dysmorphic telogen germinal units (linear columns of basaloid epithelium), trichomalacia, and inflammation. Fibrous tracts were studied for vascularity versus end-stage avascularity with fibrosis. Hair cycle was calculated by the anagen to telogen ratios and hair size by the terminal to vellus ratios.
CAPSULE SUMMARY d
A subset of breast cancer patients develops permanent alopecia after treatment with taxanes and adjuvant hormonal therapy. 
RESULTS

Patients
Table I summarizes the patients' demographics, chemotherapy, and adjuvant hormonal therapy regimens. All patients were female (10/10); 9 were white (9/10) and 1 was of Afro-Caribbean descent (1/10). The patients' age at presentation ranged from 46 to 72 years of age (mean, 56 years of age). All patients had a history of invasive ductal or lobular breast carcinoma in the 4 years before presentation. Their oncologic treatment included surgery, radiotherapy, chemotherapy, and adjuvant hormonal therapy, as per standardized protocols. Two patients (4 and 8) had been labeled as ''triple negative'' breast cancer patients and did not receive hormonal treatment. All 10 patients experienced alopecia of the scalp (10/10); additional hair loss of eyebrows and eyelashes was recorded in 3 patients (3/10) and of body hair in 5 patients (5/10).
Clinically, all patients had diffuse hair loss with residual sparse hair. Three scalp alopecia patterns were identified; these were correlated to the adjuvant hormonal therapy. Pattern type A featured diffuse alopecia with only sparse hair, and was seen in 4 patients (4/10; Figs 1 and 2). Type B featured diffuse alopecia with accentuation on the vertex of the scalp in 5 patients (5/10; Figs 3 and 4). Pattern type C had diffuse and patchy alopecia, and this was seen in 1 patient (1/10; Figs 5 and 6; Table II) .
After chemotherapy, hair regrew only partially but remained stable in 9 of 10 patients. In 1 patient (1/10; patient 3) who had only minimal hair regrowth for 2 years (and for which she was wearing a wig) experienced slow but complete hair regrowth within 6 months of starting treatment with topical minoxidil 5% (Figs 3 and 4) .
Histopathology
The histopathologic study of hair counts and hair cycle ratios are summarized in Table III . All patients showed features of nonscarring alopecia with preservation of the hair follicle units (mean, 11), reduced hair density (mean, 28), with increased telogen (mean anagen:telogen ratio, 3.1:1) and increased vellus hair follicles (mean terminal:vellus ratio, 1:1). Preservation of the sebaceous glands, miniaturization, and end-stage fibrous tracts were seen in all patients (10/10); pigment casts in telogen hair follicles were observed in 6 of 10 patients, dysmorphic telogen germinal units in 9 of 10 patients, trichomalacia in 3 of 10 patients, and a peribulbar lymphoid cell infiltrate was present in 2 of 10 patients (Table IV) .
DISCUSSION
The goal of our study was to validate the histopathologic criteria previously described in the setting of chemotherapy-induced permanent alopecia caused by taxanes in our 10 patients with breast cancer. 13, 17, 18 We also wanted to assess whether the adjuvant antiestrogen hormonal therapy may represent a cofactor in genetically susceptible individuals. Our patients had a clinicopathologic spectrum of findings that might reflect different stages of disease activity or different responses to treatment regimens.
Histopathologically, all our patients showed advanced/end-stage permanent alopecia. Features included preservation of the sebaceous glands, diffuse miniaturization of the hair follicles, and increased telogen hair follicles. Pigment casts and dystrophic telogen germinal units were observed, 12, 13 as were end-stage avascular fibrous tracts, 13 confirming permanent alopecia. This constellation of findings may be seen in both androgenic alopecia and alopecia areata. 17 Our novel observation of peribulbar lymphoid cell infiltrate in 2 different clinical presentations of our cohort offers avenues for speculation and hypothesis. While patient 3 with peribulbar lymphocytes showed no clinical features of alopecia areata and experienced a slow and steady hair regrowth with full recovery after treatment with topical minoxidil 5%, patient 10 had patchy alopecia consistent with alopecia areata. The latter was occurring on a background of diffuse sparse hairs, consistent with prior therapy with taxanes.
We propose a ''dual target'' hypothesis to explain the spectrum of our morphologic findings. The first target is the hair bulb, in response to the direct effect of chemotherapy; the second target is the residual hair follicle, which would further miniaturize in response to the antiestrogen hormonal adjuvant therapy. Chemotherapeutic agents are known to activate the dystrophic catagen response pathway to damage 19 by targeting the highly proliferative hair matrix cells of hair bulbs, 20 which are the same target in alopecia areata. Thus, it is no surprise to observe histopathologically a chemotherapy-induced bulbar response akin to alopecia areata, with anagen effluvium and alopecia areataelike histopathology. 17 As in alopecia areata, 21 the action of chemotherapeutic regimens on hair bulbs targets the follicular stem cells, but may also lead to collapse of the natural hair follicle immune privilege with exposure of hair bulb antigens, with hair bulbs vulnerability to a secondary host immune response. This would explain why patients 3 and 10 developed peribulbar lymphoid cell infiltrate, a feature characteristic of alopecia areata. Recurring chemotherapyassociated alopecia areata has been reported in 1 patient 22 ; we speculate that the alopecia areata described by the authors was triggered by the immune privilege collapse of the hair bulbs because of the chemotherapy insult, as in our patients.
We further hypothesize that hormonal antiestrogen adjuvant therapy may represent the additional factor sustaining the dystrophic catagen response pathway initiated by chemotherapy. 19, 23 This would lead to a morphologic status of ''follicular inertia'' (as observed histopathologically at the isthmus), with further miniaturization and increased telogen hair follicles, histopathologically and clinically mimicking female pattern hair loss. Antiestrogen therapy, including tamoxifen, has been associated with female pattern hair loss, [24] [25] [26] [27] [28] with ''androgenization'' of the androgen-dependent hair follicles, 29 shift into telogen, and dystrophy 30 in susceptible women. 26 Studies have shown androgen receptor expression in the outer root sheath of affected areas in patients who are taking tamoxifen. 25 In mice, hair growth arrest occurs after topical application of tamoxifen, but significant hair regrowth resumes with topical estrogen. 31 Hair regrowth has also been documented in humans who are taking low-dose oral minoxidil. 32 Our findings validate the chemotherapy-induced alopecia areataelike histopathology, but also suggest that, while the histopathologic and clinical appearances of female pattern hair loss may be initiated by chemotherapy via the dystrophic catagen pathway, antiestrogen hormonal adjuvant therapy also represents an important cofactor. Hair follicle disruption would occur in the following sequence: 1) alopecia areataelike shift out of anagen (inflammatory telogen); 2) hair follicle ''inertia''; and 3) antiestrogen androgenic miniaturization (Fig 7) .
Prospective and time-sequenced studies of scalp biopsy specimens in patients with breast cancer both before and during treatment protocols are necessary to establish the exact morphobiologic timeframe for the complex histopathologic spectrum of findings observed in chemotherapy-induced alopecia in susceptible patients.
